ThermoGenesis to develop COVID-19 therapeutics

By The Science Advisory Board staff writers

ThermoGenesis has announced that its joint venture, ImmuneCyte Life Sciences, has acquired intellectual property for developing antibody therapeutics for COVID-19.

The intellectual property ImmuneCyte has purchased includes four monoclonal antibody drug candidates against SARS-CoV-2, which were obtained from B cell samples from patients who recovered from the disease. The drug candidates were initially developed by researchers at East China Normal University in Shanghai.

ThermoGenesis is also developing a treatment called convalescent plasma therapy that gives patients a plasma infusion from people who have recovered from COVID-19 using its SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection kit, it said.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking